Meloxicam: selective COX-2 inhibition in clinical practice.
about
Pain management for rheumatoid arthritis and cardiovascular or renal comorbidityAnti-inflammatory effects of dexamethasone and meloxicam on Borrelia burgdorferi-induced inflammation in neuronal cultures of dorsal root ganglia and myelinating cells of the peripheral nervous systemTherapeutic advances in ankylosing spondylitis.Management of Inflammatory Pain with Selective COX-2 Inhibitors: Promises and Facts.Therapeutic potential of COX-2 inhibitors in arthritis.A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells.Inflammation in the pathogenesis of lyme neuroborreliosisEffects of NSAIDs on the osteogenic differentiation of human adipose tissue-derived stromal cells.A comparative study pertaining to deleterious effects of diclofenac sodium and meloxicam on kidney tissue in rats.The future of osteoarthritis therapeutics: targeted pharmacological therapyEffects of dexamethasone and meloxicam on Borrelia burgdorferi-induced inflammation in glial and neuronal cells of the central nervous system.Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancerDistribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation.Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam.Emerging evidence for inflammation in conditions frequently affecting older adults: report of a symposium.Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility.
P2860
Q24235971-D9D8D5B3-D35F-46C4-9169-39D9A6695F0FQ30395372-6BDB0A15-5B50-48CC-B04E-782CA42CA47AQ31697579-678893D3-C38D-44F9-BA07-D5C556B1DD87Q34040447-C17476E2-6787-46DF-8ECC-A2E0B4E93EC7Q34481579-1E22C4F5-0AAB-4734-948B-BFBC7BF6ECB6Q34516513-FDE22671-58CE-4F55-BB2E-D121E8757732Q35568103-DF42F6C4-6074-4A2D-852B-4E018D9B0E2BQ36103869-316A3C82-2F1A-4152-A528-879D744FF9C5Q36196134-ABFAA1CC-723F-4416-BD39-136EDC89275EQ37213622-7BEB8CF0-43CD-4E2A-B4A5-7CA02E1512ABQ37622977-FF4F5F71-6850-4E11-B478-87F916237071Q42758541-9ECB774F-6798-467A-9156-7639D7530C62Q42770871-7F8BF76F-ED7C-4627-B982-7A97EF181925Q47752791-1736671E-1088-4C03-9A50-F03912225EACQ48138953-B6D0A07A-0992-418A-A737-0CD81731C0BEQ53141633-9465EF46-6EC2-4A4B-ADA5-06EA6A4AF5C7
P2860
Meloxicam: selective COX-2 inhibition in clinical practice.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Meloxicam: selective COX-2 inhibition in clinical practice.
@en
Meloxicam: selective COX-2 inhibition in clinical practice.
@nl
type
label
Meloxicam: selective COX-2 inhibition in clinical practice.
@en
Meloxicam: selective COX-2 inhibition in clinical practice.
@nl
prefLabel
Meloxicam: selective COX-2 inhibition in clinical practice.
@en
Meloxicam: selective COX-2 inhibition in clinical practice.
@nl
P1476
Meloxicam: selective COX-2 inhibition in clinical practice.
@en
P2093
P356
10.1016/S0049-0172(97)80049-2
P433
P577
1997-06-01T00:00:00Z